Question about a product? Contact one of our experts.   Learn More >
Contact one of our experts.   Learn More >

Questions? Contact Sales:
530-303-3828
Contact Us

Bone Marrow CD34+ Stem/Progenitor Cells, Fresh

Clear

Questions about shipping? See Shipping Info

Description

CD34 is a glycosylated transmembrane protein and represents a well-established marker for human hematopoietic stem and progenitor cells in peripheral blood, bone marrow, and cord blood. CD34+ cells are self-renewing, multipotent stem cells that give rise to all blood cells of the immune system through a process called hematopoiesis. As hematopoietic stem cells progress through hematopoiesis they generate the myeloid (monocytes, macrophages, granulocytes, megakaryocytes, dendritic cells, erythrocytes) and lymphoid (T cells, B cells, NK cells) lineages. The highly specialized cells that arise from hematopoietic stem cells work collaboratively in defending the body against infection and disease.

Bone marrow mononuclear cells (MNCs) are separated from whole bone marrow by a density gradient centrifugation protocol.CD34+ cells are positively selected using immunomagnetic anti-CD34 (clone QBEND10) microbeads from bone marrow mononuclear cells. Isolated primary cells are characterized by flow cytometry to ensure a highly pure and viable cell population.

Cells were obtained using Institutional Review Board (IRB) approved consent forms and protocols.

Additional information

Anticoagulant

Format

Grade

Species

Cell and Tissue Source

Disease State

Donor Attributes

Product Information Sheet

BM CD34 – Fresh

Certificate of Analysis

Sample CoA

Material Safety Data Sheet

Bone Marrow – Fresh

Publications

  1. Eksioglu et al. (2017) Novel Therapeutic Approach to Improve Hematopoiesis in Low Risk MDS by Targeting MDSCs with the Fc-engineered CD33 Antibody BI 836858. Leukemia 1-9. doi:10.1038/leu.2017.21. Abstract
  2. Hudak et al. (2014) Glycocalyx Engineering Reveals a Siglec-Based Mechanism for NK Cell Immunoevasion. Nat Chem Biol 10: 69-75. doi:10.1038/nchembio.1388. Abstract
  3. Modarai et al. (2018) Efficient Delivery and Nuclear Uptake Is Not Sufficient to Detect Gene Editing in CD34+ Cells Directed by a Ribonucleoprotein Complex. Mol Ther Nucl Acids 11: 116-129. doi.org/10.1016/j.omtn.2018.01.013. Article
  4. Cheng et al. (2019) S100A9-Induced Overexpression of PD-1/PD-L1 Contributes to Ineffective Hematopoiesis in Myelodysplastic Syndromes. Leukemia. doi.org/10.1038/s41375-019-0397-9. Article
  5. Lo et al. (2020) Potent In Vitro Activity of β-D-4ʹ-Chloromethyl-2ʹ-Deoxy-2ʹ-Fluorocytidine Against Nipah VirusAntivir Res doi.org/10.1016/j.antiviral.2020.104712. Abstract
  6. Modarai et al. (2020) Precise and Error-Prone CRISPR-Directed Gene Editing Activity in Human CD34+ Cells Varies Widely Among Patient SamplesGene Therapy. https://doi.org/10.1038/s41434-020-00192-z. Article

Request More Information

Name(Required)
Product Interest(Required)
This field is for validation purposes and should be left unchanged.

Figure 1. Representative flow analysis of CD34+ cells enriched from bone marrow mononuclear cells prior to cryopreservation.